Your session is about to expire
← Back to Search
Chemoimmunotherapy for Glioblastoma
Study Summary
This trial will test a new treatment for brain cancer to see if it's safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have had 3 or fewer treatments for my high-grade brain tumor.I have previously received immunotherapy, like a vaccine or dendritic cell vaccine.The original tumor sample from my diagnosis is available for review.I can understand and am willing to sign the consent form.I have not had cancer (other than non-melanoma skin cancer) in the last 3 years.I have taken a pregnancy test in the last 72 hours and it was negative.I agree to use birth control during and for 4 months after the study.I am using two birth control methods or am not having sex to avoid pregnancy during and 120 days after the study.My diagnosis of glioblastoma has been confirmed by a pathology report.My tumor is located in the upper part of my brain.I can care for myself but may need occasional help.My blood and organ function tests are within the required ranges.I have finished treatment with radiation and Temozolomide for my primary tumor.
- Group 1: Pembrolizumab
- Group 2: temozolomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned temozolomide for therapeutic use?
"The safety rating for temozolomide is 1 due to the lack of clinical data available, as this drug has only recently gone through Phase 1 trials."
Is this research accepting new participants?
"As indicated by records hosted on clinicaltrials.gov, this research is actively seeking out volunteers and has been since November 1st 2022 following its most recent update from January 18th 2023."
What is the cap on enrolment in this clinical investigation?
"Confirmed. Clinicaltrials.gov attests that this medical trial, which was initially advertised on November 1st 2022, is actively searching for participants. A total of 30 individuals are required to enroll from one particular clinical site."
Share this study with friends
Copy Link
Messenger